HTG Molecular Diagnostics unterbewertet? (Seite 92)
eröffnet am 24.11.20 11:43:26 von
neuester Beitrag 26.10.23 18:42:03 von
neuester Beitrag 26.10.23 18:42:03 von
Beiträge: 926
ID: 1.334.811
ID: 1.334.811
Aufrufe heute: 0
Gesamt: 40.169
Gesamt: 40.169
Aktive User: 0
ISIN: US40434H3021 · WKN: A3D39C · Symbol: HTGMQ
0,0025
USD
0,00 %
0,0000 USD
Letzter Kurs 11.05.24 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0500 | +112,88 | |
| 4,9400 | +40,34 | |
| 2,8200 | +31,78 | |
| 2,3700 | +18,50 | |
| 0,6000 | +17,62 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2600 | -13,70 | |
| 9,80 | -14,06 | |
| 0,5051 | -14,39 | |
| 27,53 | -15,29 | |
| 2,0500 | -28,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Danke Edelweiss70 für den Link, hier noch mal der gesamte Wortlaut der gestrigen Meldung!!!
HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
PUBLISHED
JUN 22, 2021 8:00AM EDT
TUCSON, Ariz., June 22, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe. HTG has now signed EAP agreements with customers in both the US and Europe and continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.
Entering into additional EAP agreements with new and existing customers allows for additional studies which HTG believes will support validation of the HTG Transcriptome Panel’s performance requirements. This program also provides these collaborators with access to this panel in advance of the planned commercial launch in the third quarter of 2021. Through this process HTG has also received its first commercial orders for the HTG Transcriptome Panel from EAP collaborators and has signed EAP agreements with customers in both the US and Europe.
“Several prestigious cancer centers and research institutions throughout the US and Europe have expressed interest in our planned HTG Transcriptome Panel and are now participants or have indicated their intention to participate in the EAP. In the past week, we executed EAP agreements with Fundación Instituto Valenciano de Oncologia (Valencia, Spain) and Tyrolpath Obrist Brunhuber GmbH (Zams, Austria), two top European institutions at the leading edge of precision medicine solutions, with a focus on the use of novel technologies like our HTG EdgeSeq technology,” said Byron Lawson, Senior Vice President and Commercial Officer.
“We believe our first commercial orders for the HTG Transcriptome Panel in advance of our official launch demonstrates significant enthusiasm about the opportunities for this panel. We are very pleased to have initial orders from customers in both the US and Europe, and in both the academic and biopharma sectors,” Mr. Lawson continued.
About HTG:HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
PUBLISHED
JUN 22, 2021 8:00AM EDT
TUCSON, Ariz., June 22, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe. HTG has now signed EAP agreements with customers in both the US and Europe and continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.
Entering into additional EAP agreements with new and existing customers allows for additional studies which HTG believes will support validation of the HTG Transcriptome Panel’s performance requirements. This program also provides these collaborators with access to this panel in advance of the planned commercial launch in the third quarter of 2021. Through this process HTG has also received its first commercial orders for the HTG Transcriptome Panel from EAP collaborators and has signed EAP agreements with customers in both the US and Europe.
“Several prestigious cancer centers and research institutions throughout the US and Europe have expressed interest in our planned HTG Transcriptome Panel and are now participants or have indicated their intention to participate in the EAP. In the past week, we executed EAP agreements with Fundación Instituto Valenciano de Oncologia (Valencia, Spain) and Tyrolpath Obrist Brunhuber GmbH (Zams, Austria), two top European institutions at the leading edge of precision medicine solutions, with a focus on the use of novel technologies like our HTG EdgeSeq technology,” said Byron Lawson, Senior Vice President and Commercial Officer.
“We believe our first commercial orders for the HTG Transcriptome Panel in advance of our official launch demonstrates significant enthusiasm about the opportunities for this panel. We are very pleased to have initial orders from customers in both the US and Europe, and in both the academic and biopharma sectors,” Mr. Lawson continued.
About HTG:HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Quelle
HTGM Webpage
22 Juni
HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
June 22, 2021 at 8:00 AM EDT
https://htgmolecular.gcs-web.com/news-releases/news-release-…" target="_blank" rel="nofollow ugc noopener">https://htgmolecular.gcs-web.com/news-releases/news-release-…
HTGM Webpage
22 Juni
HTG Receives First Commercial Orders for its Planned HTG Transcriptome Panel and Announces the Signing of Two European Early Adopter Program Agreements
June 22, 2021 at 8:00 AM EDT
https://htgmolecular.gcs-web.com/news-releases/news-release-…" target="_blank" rel="nofollow ugc noopener">https://htgmolecular.gcs-web.com/news-releases/news-release-…
Antwort auf Beitrag Nr.: 68.563.162 von Edelweiss70 am 20.06.21 17:44:01Habe heute nochmal ein paar Stücke geschnappt und denke hier werde ich noch viel Spaß haben.Briefseiten ziehen auch schön an.
Antwort auf Beitrag Nr.: 68.515.041 von Edelweiss70 am 15.06.21 16:43:51Schöne Geldseiten am Freitag,mal sehen was die neue Woche so bringt
Antwort auf Beitrag Nr.: 68.514.006 von cyrosos am 15.06.21 15:34:11Et läuft.........
Trading Spotlight
Da geht ja richtig was voran.🙊
HTG Completes Product Design Lock for its Planned Transcriptome Panel and Announces the Signing of the Three Early Adopter Program Collaboration Agreements
https://finance.yahoo.com/news/htg-completes-product-design-…
https://finance.yahoo.com/news/htg-completes-product-design-…
Antwort auf Beitrag Nr.: 68.489.570 von cyrosos am 12.06.21 12:46:03Nein Cyrosos ich bin nur Vorarbeiter und möcte ich da garnicht mit fremden Federn schmücken aber gemeinsam werden wir eventuell ein paar Meisterstücke abliefern.
Du bist der Meister!🥳
Antwort auf Beitrag Nr.: 68.475.428 von cyrosos am 10.06.21 22:25:49Da werden wir noch Spass mit haben....
Durchsuchen
